Literature DB >> 27175273

New Abelson interactor-1 (Abi-1)-driven mechanism of acquired drug resistance.

A Chorzalska1, P M Dubielecka1.   

Abstract

Entities:  

Keywords:  Abi-1; acquired drug resistance; bone marrow microenvironment; integrin alpha 4

Year:  2014        PMID： 27175273      PMCID： PMC4851279          DOI： 10.1038/leusup.2014.4

Source DB:  PubMed          Journal:  Leuk Suppl        ISSN： 2044-5210


× No keyword cloud information.
  25 in total

1.  Charting the molecular network of the drug target Bcr-Abl.

Authors:  Marc Brehme; Oliver Hantschel; Jacques Colinge; Ines Kaupe; Melanie Planyavsky; Thomas Köcher; Karl Mechtler; Keiryn L Bennett; Giulio Superti-Furga
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-20       Impact factor: 11.205

2.  The membrane-proximal KXGFFKR motif of α-integrin mediates chemoresistance.

Authors:  Chi-Chao Liu; Pascal Leclair; Shyong Quin Yap; Chinten James Lim
Journal:  Mol Cell Biol       Date:  2013-09-03       Impact factor: 4.272

3.  Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

Authors:  David J Barnes; Danai Palaiologou; Eleni Panousopoulou; Beate Schultheis; Agnes S M Yong; Alice Wong; Laura Pattacini; John M Goldman; Junia V Melo
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

4.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Authors:  Bin Zhang; Min Li; Tinisha McDonald; Tessa L Holyoake; Randall T Moon; Dario Campana; Leonard Shultz; Ravi Bhatia
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

5.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Authors:  Amie S Corbin; Anupriya Agarwal; Marc Loriaux; Jorge Cortes; Michael W Deininger; Brian J Druker
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

Review 6.  The leukemic stem cell niche: current concepts and therapeutic opportunities.

Authors:  Steven W Lane; David T Scadden; D Gary Gilliland
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

Review 7.  Chronic myeloid leukemia stem cells.

Authors:  Edward Kavalerchik; Daniel Goff; Catriona H M Jamieson
Journal:  J Clin Oncol       Date:  2008-06-10       Impact factor: 44.544

Review 8.  Creation and characterization of E-selectin- and VCAM-1-deficient mice.

Authors:  L Kwee; D K Burns; J M Rumberger; C Norton; B Wolitzky; R Terry; K M Lombard-Gillooly; D J Shuster; F Kontgen; C Stewart
Journal:  Ciba Found Symp       Date:  1995

9.  Differential regulation of myeloid leukemias by the bone marrow microenvironment.

Authors:  Daniela S Krause; Keertik Fulzele; André Catic; Chia Chi Sun; David Dombkowski; Michael P Hurley; Sanon Lezeau; Eyal Attar; Joy Y Wu; Herbert Y Lin; Paola Divieti-Pajevic; Robert P Hasserjian; Ernestina Schipani; Richard A Van Etten; David T Scadden
Journal:  Nat Med       Date:  2013-10-27       Impact factor: 53.440

10.  Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia.

Authors:  A Chorzalska; I Salloum; H Shafqat; S Khan; P Marjon; D Treaba; C Schorl; J Morgan; C R Bryke; V Falanga; T C Zhao; J Reagan; E Winer; A J Olszewski; A S Al-Homsi; N Kouttab; P M Dubielecka
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.